NASDAQ:RLYB

Rallybio Stock Insider Trading

Healthcare > Biotechnology

Buy RLYB

*Your capital is at risk

$16.07

-0.160 (-0.99%)

At Close: Jun 03, 2026

Rallybio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.71. In total, the insiders bought 5.01M and sold 400.79K RLYB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.71
● Buy	5.01M shares
● Sell	400.79K shares
95% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence May 04, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.71. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (95% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 13, 2025 Buy	Option (Right to Buy) A-Award	Nash Christine A Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Hunt Ronald Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Chung Wendy Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Boudreau Helen M Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Mackay Martin Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Liu Hui Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Soteropoulos Paula Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Hopfner Robert Lorne Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Nash Christine A Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Hunt Ronald Director	Director	28 500 Value: $9K
May 13, 2025 Buy	Option (Right to Buy) A-Award	Chung Wendy Director	Director	28 500 Value: $9K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Lieber Jonathan I Chief Financial Officer	C-Suite Officer	180 000 Value: $136.8K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Ryder Steven Chief Medical Officer	Officer	180 000 Value: $136.8K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Uden Stephen Chief Executive Officer	CEO / President	453 700 Value: $344.8K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Lieber Jonathan I Chief Financial Officer	C-Suite Officer	180 000 Value: $136.8K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Ryder Steven Chief Medical Officer	Officer	180 000 Value: $136.8K
Feb 14, 2025 Buy	Option (Right to Buy) A-Award	Uden Stephen Chief Executive Officer	CEO / President	453 700 Value: $344.8K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Liu Hui Director	Director	67 857 Value: $64.5K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Hopfner Robert Lorne Director	Director	73 571 Value: $69.9K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Hunt Ronald Director	Director	73 571 Value: $69.9K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Mackay Martin Director	Director	92 857 Value: $88.2K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Liu Hui Director	Director	67 857 Value: $64.5K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Hopfner Robert Lorne Director	Director	73 571 Value: $69.9K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Hunt Ronald Director	Director	73 571 Value: $69.9K
Jan 02, 2025 Buy	Option (Right to Buy) A-Award	Mackay Martin Director	Director	92 857 Value: $88.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RALLYBIO CORPORATION

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclona...

Read Full Profile Here